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The potential value of biological markers in the management of
cancer has been emphasized in several recent articles (Dowsett,
1998; Ad-hoc Biomarkers Group of UKCCCR, 2000). The
focusing of cancer services within the UK and the proposals from
the EORTC and others that any new clinical trials should include
biomarker studies should mean that more centres will be under-
taking biomarker analyses. Whilst the wider use of markers is to
be applauded it does bring with it various potential problems 
that must be addressed, particularly in relation to methodology,
quantification and defining cut-off points.
Biological markers can be determined in urine, serum and
tissues. For urine and serum, a form of immunoassay is used,
which allows quantification. However, for the markers to be of any
use they have to be sensitive and specific, tests have to be reliable
and the person using it has to be aware of any problems. For
example, measurement of serum carcinoembryonic antigen (CEA)
can be of value for monitoring colorectal cancer, but there are 
the following problems: smokers have higher circulating CEA
concentrations than non-smokers; serum CEA can be elevated in a
variety of acute and chronic inflammatory conditions; CEA can be
elevated in cancers other than colorectal cancer. Although an
individual CEA test kit gives comparable results, different CEA
test methods do not give equivalent CEA values for individual
samples, so the same test method should be used for a given
patient (American Society of Clinical Oncology, 1999). If sero-
logical markers are to be used to monitor cancer progression or
response to therapy, the test (and the laboratory) has to give repro-
ducible, reliable results on repeated measures (Helzlsouer, 1994)
and within defined limits in an external quality assurance (QA)
system.
Determination of biological markers in tissues has more scope
and there have been important changes that have occurred over
the past 25 years. Immunoassays and saturation binding assays
using homogenates of tissue, which had to be frozen promptly
after removal, have been the main methods used. These have the
drawback that tumours have to be obtained fresh, tissue snap-
frozen, stored correctly and cytosols prepared in defined buffers,
which limits their availability. Their advantage is that a numerical
result can be obtained, e.g. Scatchard analysis of the dextran-
coated charcoal radioactive ligand binding assay for oestrogen
receptor (ER) is reported as femtomoles of oestradiol bound per
mg of cytosol protein. The results can be divided into positive and
negative on the basis of the clinical cut-off value of 10 fmol mg–1
protein, and different sub-groups evaluated (Hawkins et al, 1980).
However, problems can arise with quantification, as shown by the
wide coefficient of variations found for enzyme-linked immuno-
sorbent assay (ELISA) analysis of urokinase-type plasminogen
activator in breast cancer cytosols (Sweep et al, 1998). Data from
trans-European studies has shown that for multicentre studies the
same ELISA kit should be used, that external QA is mandatory
and standardization of protein assays is imperative.
The introduction of antibodies directed against biological
markers that can be applied to fixed tissue and improvements in
antigen retrieval techniques (e.g. pressure cookers!) has meant that
many laboratories have changed to immunohistochemical methods
and also that many more laboratories are determining biological
markers. This is a positive development but it is very important
that there is standardization of all aspects of the assessment.
Critical areas include adequate, prompt fixation (analogous with
freezing tissues properly) so that there is even penetration of the
whole tissue, the use of a carefully evaluated antibody, controlled
antigen retrieval and a sensitive immunohistochemical detection
method. Positive and negative controls are critical for each batch
of staining. There have been issues as to whether there is a
deterioration in immunoreactivity of certain antigens, e.g. p53,
with storage of paraffin sections. While it is important to have in-
house checks about the latter, probably more important is the use
of optimally prepared tissues and a sensitive reliable method
(Cooper et al, 1998).
Any assay that is to be used clinically must have good QA
procedures. These exist for cytosol assays, e.g. ER, and there are
excellent quality assurance schemes organized by the EORTC
(Romain et al, 1995). An essential feature of these schemes is that
they use a stable, easily distributed standard material and that
quantitative elements of the assay are assessed. There are QA
schemes for checking immunohistochemical staining (e.g. UK
NEQAS ICC), to try and standardize methodology between labo-
ratories. The problem comes with the quantification of immuno-
histochemistry and how it should be standardized. Defining
clinically relevant cut-off values can be more difficult. ER again
provides a good example; a variety of scoring systems have been
used but they are subjective and semi-quantitative. Cut-off values
for positive and negative, or response/non-response to endocrine
treatment may vary depending on whether it is for adjuvant use or
for treating metastatic disease. If, as for the former, the cut-off
levels are low (Elledge and Osborne, 1997) then the methods and
interpretation have to have a high sensitivity. QA of interpretation
is just as important as that for the methods (Barnes et al, 1998). For
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immunohistochemistry does have advantages.
The future is certainly brighter for biological markers but could
be dimmed unless important standards are maintained.
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